The Lancet Haematology, a premier international hematology journal, has published the results of a groundbreaking clinical study evaluating Leman Biotech’s metabolically armored CD19 CAR-T therapy (Meta10-19) in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). This study marks a major milestone in the advancement of next-generation CAR-T therapies.

Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug (formerly ALXN2220, NI006) for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who were previously enrolled in the proof-of-concept study NI006-101 (NCT04360434). Cliramitug is an investigational human monoclonal antibody designed to deplete amyloid deposits in

Nouscom presents positive Phase 2 results of NOUS-209 immunotherapy combined with Pembrolizumab in MSI-H metastatic colorectal cancer patients refractory to Anti-PD-1 therapy, at ESMO 2025.

abc biopply ag, a Swiss biotech company specializing in humanized 3D disease models, and Inoviem Scientific, have entered a strategic collaboration to develop and commercialize a new preclinical service for the pharmaceutical industry creating a patient-relevant drug testing platform by uniquely integrating Inoviem’s direct access to fresh patient tumor biopsies with abc biopply’s proprietary

Celonic Group one of the leading “pureplay” Biologics CDMO, and The Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics ca

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, announces the appointment of Sabine Moravi as an Associate Partner. This strategic hire marks a significant step in the firm’s expansion within the Swiss market and the broader DACH region.